Biotechnology Assets S.A. (BST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotechnology Assets S.A. (BST) has a cash flow conversion efficiency ratio of 0.102x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€658.13K ≈ $769.43K USD) by net assets (€6.45 Million ≈ $7.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BST equity to assets ratio to measure how much of total assets are equity-financed.
Biotechnology Assets S.A. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Biotechnology Assets S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BST cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Biotechnology Assets S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotechnology Assets S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scienture Holdings, Inc.
NASDAQ:SCNX
|
0.000x |
|
Sejoong Co. Ltd
KQ:039310
|
-0.005x |
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
-9.243x |
|
Sunrise New Energy Co. Ltd
NASDAQ:EPOW
|
-0.678x |
|
Saray Matbaacilik Kagitcilik Kirtasiyecilik Ticaret ve Sanayi AS
IS:SAMAT
|
-0.082x |
|
Winhitech Co Ltd
KQ:192390
|
-0.079x |
|
Volt Carbon Technologies Inc
V:VCT
|
-0.075x |
|
Xinyuan Real Estate Co Ltd
NYSE:XIN
|
-0.644x |
Annual Cash Flow Conversion Efficiency for Biotechnology Assets S.A. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Biotechnology Assets S.A. from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Biotechnology Assets S.A. (BST) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €6.61 Million ≈ $7.73 Million |
€-73.85K ≈ $-86.34K |
-0.011x | -252.87% |
| 2023-12-31 | €6.53 Million ≈ $7.64 Million |
€47.74K ≈ $55.81K |
0.007x | +101.63% |
| 2022-12-31 | €3.87 Million ≈ $4.53 Million |
€-1.73 Million ≈ $-2.03 Million |
-0.447x | -29.25% |
| 2021-12-31 | €4.34 Million ≈ $5.07 Million |
€-1.50 Million ≈ $-1.76 Million |
-0.346x | -115.13% |
| 2020-12-31 | €3.84 Million ≈ $4.49 Million |
€8.79 Million ≈ $10.28 Million |
2.288x | +214.10% |
| 2019-12-31 | €7.56 Million ≈ $8.84 Million |
€-15.16 Million ≈ $-17.72 Million |
-2.005x | -226.35% |
| 2018-12-31 | €21.19 Million ≈ $24.78 Million |
€-13.02 Million ≈ $-15.23 Million |
-0.614x | -2410.54% |
| 2017-12-31 | €8.03 Million ≈ $9.38 Million |
€213.49K ≈ $249.59K |
0.027x | -92.21% |
| 2016-12-31 | €7.96 Million ≈ $9.30 Million |
€2.71 Million ≈ $3.17 Million |
0.341x | +1533.30% |
| 2015-12-31 | €7.57 Million ≈ $8.85 Million |
€158.16K ≈ $184.90K |
0.021x | +152.79% |
| 2014-12-31 | €7.68 Million ≈ $8.97 Million |
€-303.79K ≈ $-355.16K |
-0.040x | -- |
About Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more